These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35980242)

  • 21. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome.
    Rebuffé-Scrive M; Krotkiewski M; Elfverson J; Björntorp P
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1122-8. PubMed ID: 3142910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome.
    Escoté X; Aranda GB; Mora M; Casals G; Enseñat J; Vidal O; Esteban Y; Halperin I; Hanzu FA
    Endocrinol Diabetes Nutr; 2017 Jan; 64(1):26-33. PubMed ID: 28440767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome.
    Christ-Crain M; Kola B; Lolli F; Fekete C; Seboek D; Wittmann G; Feltrin D; Igreja SC; Ajodha S; Harvey-White J; Kunos G; Müller B; Pralong F; Aubert G; Arnaldi G; Giacchetti G; Boscaro M; Grossman AB; Korbonits M
    FASEB J; 2008 Jun; 22(6):1672-83. PubMed ID: 18198220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission.
    Schernthaner-Reiter MH; Siess C; Gessl A; Scheuba C; Wolfsberger S; Riss P; Knosp E; Luger A; Vila G
    Endocrine; 2019 Apr; 64(1):157-168. PubMed ID: 30467627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma leptin levels in relation to body composition and body fat distribution in patients with Cushing's syndrome].
    Robaczyk M; Krzyzanowiska-Swiniarska B; Andrysiak-Mamos E; Kulig G; Pilarska K
    Pol Arch Med Wewn; 2003 Nov; 110(5):1299-308. PubMed ID: 16737000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome.
    Macfarlane DP; Forbes S; Walker BR
    J Endocrinol; 2008 May; 197(2):189-204. PubMed ID: 18434349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.
    Tarantino G; Finelli C
    World J Gastroenterol; 2013 Oct; 19(40):6735-43. PubMed ID: 24187449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucocorticoids and Metabolic Control.
    Magomedova L; Cummins CL
    Handb Exp Pharmacol; 2016; 233():73-93. PubMed ID: 25917083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of selected angiogenesis-related small microRNAs in patients with abnormally increased secretion of glucocorticoids.
    Kawa MP; Sobuś A; Litwińska Z; Osowicz-Korolonek L; Cymbaluk-Płoska A; Stecewicz I; Zagrodnik E; Romanowska H; Walczak M; Syrenicz A; Machaliński B
    Endokrynol Pol; 2019; 70(6):489-495. PubMed ID: 31909455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cushing's Syndrome Effects on the Thyroid.
    Paragliola RM; Corsello A; Papi G; Pontecorvi A; Corsello SM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucocorticoid-Induced Fatty Liver Disease.
    Rahimi L; Rajpal A; Ismail-Beigi F
    Diabetes Metab Syndr Obes; 2020; 13():1133-1145. PubMed ID: 32368109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical investigation on the mechanism of glucose intolerance in Cushing's syndrome].
    Takeda N; Yasuda K; Horiya T; Yamada H; Imai T; Kitada M; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1986 May; 62(5):631-48. PubMed ID: 3525245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess.
    Pivonello R; De Martino MC; Iacuaniello D; Simeoli C; Muscogiuri G; Carlomagno F; De Leo M; Cozzolino A; Colao A
    Front Horm Res; 2016; 46():54-65. PubMed ID: 27212264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of glucocorticoids on adipose tissue lipid metabolism.
    Peckett AJ; Wright DC; Riddell MC
    Metabolism; 2011 Nov; 60(11):1500-10. PubMed ID: 21864867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endurance exercise training increases adipose tissue glucocorticoid exposure: adaptations that facilitate lipolysis.
    Campbell JE; Fediuc S; Hawke TJ; Riddell MC
    Metabolism; 2009 May; 58(5):651-60. PubMed ID: 19375588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in Cushing's disease: a minimal model analysis.
    Page R; Boolell M; Kalfas A; Sawyer S; Pestell R; Ward G; Alford F
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):509-17. PubMed ID: 1769133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management.
    Scaroni C; Zilio M; Foti M; Boscaro M
    Endocr Rev; 2017 Jun; 38(3):189-219. PubMed ID: 28368467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.
    Lewis GF; Carpentier A; Adeli K; Giacca A
    Endocr Rev; 2002 Apr; 23(2):201-29. PubMed ID: 11943743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI.
    Geer EB; Shen W; Strohmayer E; Post KD; Freda PU
    J Clin Endocrinol Metab; 2012 May; 97(5):1702-11. PubMed ID: 22419708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.